Adverse Outcome Pathway on impaired interleukin-1 receptor type I (IL-1R1) signaling leading to impaired T-cell dependent antibody response:
Stressors that exhibit immunosuppression might act by different mechanisms, i.e. alter the number of cells involved in the immune response, the ability of the cells to produce cytokines, chemokines, antibodies or growth factors, the composition of the subpopulations of cells present at the site of t...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , |
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Paris
OECD Publishing
2023
|
| Series: | OECD Series on Adverse Outcome Pathways
no.30 |
| Subjects: | |
| Online Access: | DE-862 DE-863 |
| Summary: | Stressors that exhibit immunosuppression might act by different mechanisms, i.e. alter the number of cells involved in the immune response, the ability of the cells to produce cytokines, chemokines, antibodies or growth factors, the composition of the subpopulations of cells present at the site of the response, or the function of the cells. This Adverse Outcome Pathway (AOP) describes how impairment of the signaling receptor IL-1R1 in T cells can lead to impaired T cell activation and antibody production, leading to increased susceptibility to infection. The AOP focuses on the blocking of binding of IL-1 to IL-1R1, leading to the Inhibition of Nuclear factor kappa B (NF-kB). This AOP is referred to as AOP 277 in the Collaborative Adverse Outcome Pathway Wiki (AOP-Wiki). |
| Physical Description: | 1 Online-Ressource (59 Seiten) 21 x 28cm. |
Staff View
MARC
| LEADER | 00000cam a22000002 4500 | ||
|---|---|---|---|
| 001 | ZDB-13-SOC-098550667 | ||
| 003 | DE-627-1 | ||
| 005 | 20241028113958.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231204s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1787/74834ad1-en |2 doi | |
| 035 | |a (DE-627-1)098550667 | ||
| 035 | |a (DE-599)KEP098550667 | ||
| 035 | |a (FR-PaOEC)74834ad1-en | ||
| 035 | |a (DE-627-1)098550667 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kimura, Yutaka |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a Adverse Outcome Pathway on impaired interleukin-1 receptor type I (IL-1R1) signaling leading to impaired T-cell dependent antibody response |c Yutaka, Kimura ... [et al] |
| 264 | 1 | |a Paris |b OECD Publishing |c 2023 | |
| 300 | |a 1 Online-Ressource (59 Seiten) |c 21 x 28cm. | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a OECD Series on Adverse Outcome Pathways |v no.30 | |
| 520 | |a Stressors that exhibit immunosuppression might act by different mechanisms, i.e. alter the number of cells involved in the immune response, the ability of the cells to produce cytokines, chemokines, antibodies or growth factors, the composition of the subpopulations of cells present at the site of the response, or the function of the cells. This Adverse Outcome Pathway (AOP) describes how impairment of the signaling receptor IL-1R1 in T cells can lead to impaired T cell activation and antibody production, leading to increased susceptibility to infection. The AOP focuses on the blocking of binding of IL-1 to IL-1R1, leading to the Inhibition of Nuclear factor kappa B (NF-kB). This AOP is referred to as AOP 277 in the Collaborative Adverse Outcome Pathway Wiki (AOP-Wiki). | ||
| 650 | 4 | |a Environment | |
| 700 | 1 | |a Aiba, Setsuya |e MitwirkendeR |4 ctb | |
| 700 | 1 | |a Ashikaga, Takao |e MitwirkendeR |4 ctb | |
| 700 | 1 | |a Ohishi, Takumi |e MitwirkendeR |4 ctb | |
| 700 | 1 | |a Kushima, Kiyoshi |e MitwirkendeR |4 ctb | |
| 966 | 4 | 0 | |l DE-862 |p ZDB-13-SOC |q FWS_PDA_SOC |u https://doi.org/10.1787/74834ad1-en |m X:OECD |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 966 | 4 | 0 | |l DE-863 |p ZDB-13-SOC |q FWS_PDA_SOC |u https://doi.org/10.1787/74834ad1-en |m X:OECD |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 912 | |a ZDB-13-SOC-ebook | ||
| 912 | |a ZDB-13-SOC | ||
| 951 | |a BO | ||
| 912 | |a ZDB-13-SOC | ||
| 049 | |a DE-862 | ||
| 049 | |a DE-863 | ||
Record in the Search Index
| DE-BY-FWS_katkey | ZDB-13-SOC-098550667 |
|---|---|
| _version_ | 1826942499196764160 |
| adam_text | |
| any_adam_object | |
| author | Kimura, Yutaka |
| author2 | Aiba, Setsuya Ashikaga, Takao Ohishi, Takumi Kushima, Kiyoshi |
| author2_role | ctb ctb ctb ctb |
| author2_variant | s a sa t a ta t o to k k kk |
| author_facet | Kimura, Yutaka Aiba, Setsuya Ashikaga, Takao Ohishi, Takumi Kushima, Kiyoshi |
| author_role | aut |
| author_sort | Kimura, Yutaka |
| author_variant | y k yk |
| building | Verbundindex |
| bvnumber | localFWS |
| collection | ZDB-13-SOC-ebook ZDB-13-SOC |
| ctrlnum | (DE-627-1)098550667 (DE-599)KEP098550667 (FR-PaOEC)74834ad1-en |
| discipline | Wirtschaftswissenschaften |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02159cam a22003852 4500</leader><controlfield tag="001">ZDB-13-SOC-098550667</controlfield><controlfield tag="003">DE-627-1</controlfield><controlfield tag="005">20241028113958.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">231204s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1787/74834ad1-en</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627-1)098550667</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)KEP098550667</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(FR-PaOEC)74834ad1-en</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627-1)098550667</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kimura, Yutaka</subfield><subfield code="e">VerfasserIn</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Adverse Outcome Pathway on impaired interleukin-1 receptor type I (IL-1R1) signaling leading to impaired T-cell dependent antibody response</subfield><subfield code="c">Yutaka, Kimura ... [et al]</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Paris</subfield><subfield code="b">OECD Publishing</subfield><subfield code="c">2023</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (59 Seiten)</subfield><subfield code="c">21 x 28cm.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">OECD Series on Adverse Outcome Pathways</subfield><subfield code="v">no.30</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Stressors that exhibit immunosuppression might act by different mechanisms, i.e. alter the number of cells involved in the immune response, the ability of the cells to produce cytokines, chemokines, antibodies or growth factors, the composition of the subpopulations of cells present at the site of the response, or the function of the cells. This Adverse Outcome Pathway (AOP) describes how impairment of the signaling receptor IL-1R1 in T cells can lead to impaired T cell activation and antibody production, leading to increased susceptibility to infection. The AOP focuses on the blocking of binding of IL-1 to IL-1R1, leading to the Inhibition of Nuclear factor kappa B (NF-kB). This AOP is referred to as AOP 277 in the Collaborative Adverse Outcome Pathway Wiki (AOP-Wiki).</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Environment</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aiba, Setsuya</subfield><subfield code="e">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ashikaga, Takao</subfield><subfield code="e">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ohishi, Takumi</subfield><subfield code="e">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kushima, Kiyoshi</subfield><subfield code="e">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="966" ind1="4" ind2="0"><subfield code="l">DE-862</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="q">FWS_PDA_SOC</subfield><subfield code="u">https://doi.org/10.1787/74834ad1-en</subfield><subfield code="m">X:OECD</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="4" ind2="0"><subfield code="l">DE-863</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="q">FWS_PDA_SOC</subfield><subfield code="u">https://doi.org/10.1787/74834ad1-en</subfield><subfield code="m">X:OECD</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC-ebook</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">BO</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-862</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-13-SOC-098550667 |
| illustrated | Not Illustrated |
| indexdate | 2025-03-18T14:28:58Z |
| institution | BVB |
| language | English |
| open_access_boolean | |
| owner | DE-862 DE-BY-FWS DE-863 DE-BY-FWS |
| owner_facet | DE-862 DE-BY-FWS DE-863 DE-BY-FWS |
| physical | 1 Online-Ressource (59 Seiten) 21 x 28cm. |
| psigel | ZDB-13-SOC FWS_PDA_SOC ZDB-13-SOC-ebook ZDB-13-SOC |
| publishDate | 2023 |
| publishDateSearch | 2023 |
| publishDateSort | 2023 |
| publisher | OECD Publishing |
| record_format | marc |
| series2 | OECD Series on Adverse Outcome Pathways |
| spelling | Kimura, Yutaka VerfasserIn aut Adverse Outcome Pathway on impaired interleukin-1 receptor type I (IL-1R1) signaling leading to impaired T-cell dependent antibody response Yutaka, Kimura ... [et al] Paris OECD Publishing 2023 1 Online-Ressource (59 Seiten) 21 x 28cm. Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier OECD Series on Adverse Outcome Pathways no.30 Stressors that exhibit immunosuppression might act by different mechanisms, i.e. alter the number of cells involved in the immune response, the ability of the cells to produce cytokines, chemokines, antibodies or growth factors, the composition of the subpopulations of cells present at the site of the response, or the function of the cells. This Adverse Outcome Pathway (AOP) describes how impairment of the signaling receptor IL-1R1 in T cells can lead to impaired T cell activation and antibody production, leading to increased susceptibility to infection. The AOP focuses on the blocking of binding of IL-1 to IL-1R1, leading to the Inhibition of Nuclear factor kappa B (NF-kB). This AOP is referred to as AOP 277 in the Collaborative Adverse Outcome Pathway Wiki (AOP-Wiki). Environment Aiba, Setsuya MitwirkendeR ctb Ashikaga, Takao MitwirkendeR ctb Ohishi, Takumi MitwirkendeR ctb Kushima, Kiyoshi MitwirkendeR ctb |
| spellingShingle | Kimura, Yutaka Adverse Outcome Pathway on impaired interleukin-1 receptor type I (IL-1R1) signaling leading to impaired T-cell dependent antibody response Environment |
| title | Adverse Outcome Pathway on impaired interleukin-1 receptor type I (IL-1R1) signaling leading to impaired T-cell dependent antibody response |
| title_auth | Adverse Outcome Pathway on impaired interleukin-1 receptor type I (IL-1R1) signaling leading to impaired T-cell dependent antibody response |
| title_exact_search | Adverse Outcome Pathway on impaired interleukin-1 receptor type I (IL-1R1) signaling leading to impaired T-cell dependent antibody response |
| title_full | Adverse Outcome Pathway on impaired interleukin-1 receptor type I (IL-1R1) signaling leading to impaired T-cell dependent antibody response Yutaka, Kimura ... [et al] |
| title_fullStr | Adverse Outcome Pathway on impaired interleukin-1 receptor type I (IL-1R1) signaling leading to impaired T-cell dependent antibody response Yutaka, Kimura ... [et al] |
| title_full_unstemmed | Adverse Outcome Pathway on impaired interleukin-1 receptor type I (IL-1R1) signaling leading to impaired T-cell dependent antibody response Yutaka, Kimura ... [et al] |
| title_short | Adverse Outcome Pathway on impaired interleukin-1 receptor type I (IL-1R1) signaling leading to impaired T-cell dependent antibody response |
| title_sort | adverse outcome pathway on impaired interleukin 1 receptor type i il 1r1 signaling leading to impaired t cell dependent antibody response |
| topic | Environment |
| topic_facet | Environment |
| work_keys_str_mv | AT kimurayutaka adverseoutcomepathwayonimpairedinterleukin1receptortypeiil1r1signalingleadingtoimpairedtcelldependentantibodyresponse AT aibasetsuya adverseoutcomepathwayonimpairedinterleukin1receptortypeiil1r1signalingleadingtoimpairedtcelldependentantibodyresponse AT ashikagatakao adverseoutcomepathwayonimpairedinterleukin1receptortypeiil1r1signalingleadingtoimpairedtcelldependentantibodyresponse AT ohishitakumi adverseoutcomepathwayonimpairedinterleukin1receptortypeiil1r1signalingleadingtoimpairedtcelldependentantibodyresponse AT kushimakiyoshi adverseoutcomepathwayonimpairedinterleukin1receptortypeiil1r1signalingleadingtoimpairedtcelldependentantibodyresponse |